- 询价
- SignaGen
- 美国
- SignaGen
- 2026年01月06日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
4°C
- 保质期：
1年
- 英文名：
Pre-packaged AAV
- 库存：
现货 大量
- 供应商：
济南思科生物科技有限公司
Pre-packaged AAV:
All the following pre-packaged AAVs were pre-made with serotype 1**, 2, 5, 6, 8** and 9** as controls. All the pre-packaged rAAVs were titered via qPCR, packed in sterile PBS and in ready-to-use format.
|
Catalog # |
Product |
Titer |
Size * |
Price |
|
AAV-Null (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-miRNA(scramble)-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Null (AAV Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-U6-miRNA(scramble)-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre (Serotype 2) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre-GFP (Serotype 2) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-tdTOMATO (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-tdTOMATO (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-Null (AAV Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-miRNA(scramble)-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-RFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
|
||||
|
AAV-Null (AAV Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-RFP (Serotype 6) |
> 1x1013 VG/ml |
> 20 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
|
||||
|
AAV-Null (AAV Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-Cre (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-Cre-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Null (AAV Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 9, Self-complementary) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 9, Self-complementary) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-CMV-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-EF1a-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-Cre (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-Cre-GFP (Serotype 9) |
&g, t;, 1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-shRNA(scramble) (serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
|
||||
|
AAV Serotypes Testing Kit |
|
|
|
|
|
AAV Serotypes Testing Kit |
1x1012~1x1013 VG/ml |
6 x 200 μl |
$2342 |
|
* All our pre-made rAAVs are super purified (in vivo grade) via advanced CsCl ultra-centrifugation and Ok to inject directly to animals. The titer of pre-made rAAVs as determined via qPCR is highly dependent upon transgene and serotypes and varies from batch to batch. For standard packs, we offer >30 μl of pre-made rAAVs at >1E+13 VG/ml or >200 μl at >1E+12 VG/ml. For trial packs, we offer >10 μl of pre-made rAAVs at >1E+13 VG/ml or >70 μl at >1E+12 VG/ml.
更多详情：http://www.qswbio.com/gb17695.html
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验小鼠实验 AAV 载体包装能力有限性 大基因片段分两段用不同的载体分别进入体内，在体内进行同源重组 目的基因表达蛋白的轻链和重链放在不同载体上，在体内表内后也会自己重组 遗传毒性 肝细胞的自我更新增加 AAV 基因整合到小鼠体内基因组上的概率，AAV 基因组整合诱导小鼠肝细胞癌（HCC）的发生。
腺相关病毒（AAV）作为一种安全、持久、高效、高特异性的基因操作工具，在生物学特别是神经生物学领域中被广泛使用。许多新手对于 AAV 的使用往往是知其然而不知其所以然。这篇短文将以图文结合的形式争取让大家在最短的时间内全面了解这种病毒工具。 什么是 AAV？ 野生型 AAV 是一种复制缺陷型微小病毒，需要腺病毒或疱疹病毒帮助其在体内复制扩增。而我们做实验用的是不需要辅助病毒的重组 AAV 病毒（rAAV）。将目的基因的 CDS 区序列或者 RNAi 干扰序列插入 rAAV 表达质粒中，包装病毒
1、研究中该如何选择 AAV 血清型和剂量？ 您可以在我们的血清型选择指南中找到所有血清型和组织趋向性的介绍。 2、重组 AAV 是复制缺陷的吗？ 对于野生型 AAV，如果没有辅助病毒（如腺病毒）的存在，其复制效率极低。对于现在生产的重组 AAV，复制和衣壳基因是在 Rep/Cap 质粒中提供的。只有 AAV 基因组的两个 ITR（倒置末端重复序列）被保留并包装成病毒颗粒，而所需的腺病毒基因要么是由腺病毒提供的，要么是由另一个质粒提供的。理论上，重组 AAV 是不可能复制的。 3、AAV
技术资料暂无技术资料 索取技术资料
